TRIM29: A New Target in Treatment of Squamous Cell Carcinoma?
A new study inCancer Research evaluated the function of TRIM29 in regulating  keratin distribution and migration/invasion of SCC. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

CNIO and Hospital 12 de Octubre extend effectiveness of immunotherapy to more lung cancer patients
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients.Squamous cell carcinoma represents 20 percent to 30 percent of all cases of lung cancer and has a worse prognosis than other variants. It has the least amount of progress in terms of treatment.Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2018 Category: International Medicine & Public Health Source Type: news

How Useful Are Immune Checkpoint Markers in Squamous Cell Carcinoma?
A recent study examined the literature on whether immune checkpoint molecules improve overall survival in oral squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - November 29, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Skin cancer rates far higher than previously thought, according to new national database
(Queen Mary University of London) Data from a newly established UK skin cancer database, the largest of its kind in the world, has revealed that there are over 45,000 cutaneous squamous cell carcinomas every year in England, 350 percent more than previous estimates suggested. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 28, 2018 Category: International Medicine & Public Health Source Type: news

Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Biomarker blood test confirms remission in patients with HPV+ oral cancer
(American Society for Radiation Oncology) A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2018 Category: Cancer & Oncology Source Type: news

HPV blood test shows promise for tracking head and neck cancer after treatment
(UNC Lineberger Comprehensive Cancer Center) Researchers will present preliminary findings at the 60th Annual Meeting of the American Society for Radiation Oncology in San Antonio on Tuesday, Oct. 23, from a study that evaluated a blood test for HPV-linked oropharyngeal squamous cell carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 23, 2018 Category: Cancer & Oncology Source Type: news

NUS researchers elucidate roles TP63 and SOX2 in squamous cell cancer progression
(National University of Singapore) Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have identified a SCC-specific protein complex activated by TP63 and SOX2 which triggers a gene cascade that promotes SCC growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 14, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves First Drug for Advanced cSCC
Cemiplimab (Libtayo), approved for advanced cutaneous squamous cell carcinoma, is intended for those not eligible for curative surgery or radiation. (Source: CancerNetwork)
Source: CancerNetwork - October 10, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Increased survival in patients with metastatic NSCLC receiving treatment in academic centers
(International Association for the Study of Lung Cancer) Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs). An overall histology-dependent survival was also noted in patients with adenocarcinoma verses squamous cell carcinoma and varied by treatment facility. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 10, 2018 Category: Cancer & Oncology Source Type: news

FDA approves Sanofi and Regeneron's skin cancer med
The imunotherapy Libtayo can treat patients with particular kinds of cutaneous squamous cell carcinoma. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 2, 2018 Category: Pharmaceuticals Source Type: news

' Transformational' Results in Squamous Cell Lung Cancer'Transformational' Results in Squamous Cell Lung Cancer
An immuno-chemotherapy combination again moves the bar forward in a difficult-to-treat subset of squamous cell lung cancer patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves New Treatment for Squamous Cell Carcinoma
Libtayo is the sixth FDA - approved immune checkpoint inhibitor targeting the PD - 1 pathway (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 2, 2018 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Institutional, Source Type: news

First treatment approved for common form of advanced skin cancer
The FDA has approved the first treatment for patients with metastatic cutaneous squamous cell carcinoma who are not candidates for surgery or radiation. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 1, 2018 Category: Consumer Health News Source Type: news

FDA Approves Cemiplimab, First Drug for Advanced CSCC FDA Approves Cemiplimab, First Drug for Advanced CSCC
The US Food and Drug Administration today approved cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced, unresectable CSCC.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma
September 28, 2018 -- The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 28, 2018 Category: Drugs & Pharmacology Source Type: news

FDA approves first treatment for advanced form of the second most common skin cancer
FDA approves Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news

FDA approves first treatment for advanced form of the second most common skin cancer
The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC. (Source: World Pharma News)
Source: World Pharma News - September 28, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

DNA vaccine leads to immune responses in HPV-related head and neck cancer
(University of Pennsylvania School of Medicine) A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with advanced head and neck squamous cell carcinoma (HNSCCa) and found 86 percent showed elevated T cell activity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2018 Category: Cancer & Oncology Source Type: news

CRISPR screen reveals new targets in more than half of all squamous cell carcinomas
(University of Colorado Anschutz Medical Campus) Team of University of Colorado Cancer Center researchers sheds light on p63 activity in squamous cell carcinoma of the lung, providing an actionable path forward to drug development against this known cause of cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 18, 2018 Category: International Medicine & Public Health Source Type: news

Total of 43,371 New Cases of HPV-Associated Cancers in 2015
TUESDAY, Sept. 11, 2018 -- A total of 43,371 new cases of human papillomavirus (HPV)-associated cancers were reported in 2015, with oropharyngeal squamous cell carcinoma (SCC) being the most common HPV-associated cancer, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 11, 2018 Category: Pharmaceuticals Source Type: news

Study links widely-used drug azathioprine to skin cancers
(University of Dundee) A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important contributor to skin cancer development.The research, published in Nature Communications, identified a `strong case for an association' between the drug azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2018 Category: Cancer & Oncology Source Type: news

Study links widely used drug azathioprine to skin cancers
(University of Dundee) A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important contributor to skin cancer development.The research, published in Nature Communications, identified a 'strong case for an association' between the drug azathioprine and the mutational signature found in cases of cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 10, 2018 Category: Cancer & Oncology Source Type: news

Gene Variant Linked to Risk of Oral Squamous Cell Carcinoma
A study shows significant association between MTHFR C677T polymorphisms and risk of oral squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - September 7, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Voriconazole May Boost Risk of Squamous Cell Carcinoma in Transplant Patients Voriconazole May Boost Risk of Squamous Cell Carcinoma in Transplant Patients
Recipients of lung transplants (LT) or hematopoietic cell transplants (HCT) who are taking the antifungal voriconazole may be at increased risk of squamous cell carcinoma (SCC), researchers report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 7, 2018 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Manual vs Automated Squamous Cell Carcinoma Antigen Assays Manual vs Automated Squamous Cell Carcinoma Antigen Assays
Does the automated Elecsys SCC assay provide comparable performance to a manual assay for determining squamous cell carcinoma antigen levels?Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Radn Tx Alone May Be Adequate for Stage I Anal Cancer in Elderly
THURSDAY, Aug. 30, 2018 -- For older patients with stage I squamous cell carcinoma of the anus, radiation alone is associated with outcomes that do not differ significantly from those of chemoradiation, according to research published in the July... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 30, 2018 Category: Pharmaceuticals Source Type: news

Alpha Tau wins approval to test cancer-targeting device in the U.S.
  Image courtesy of Alpha Tau Medical. Alpha Tau Medical can begin U.S. clinical trials of its cancer-zapping device, thanks to a new permit from the Massachusetts Radiation Control Program. The state agency granted a Sealed Source and Device (SSD) approval to the Tel Aviv company’s Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy), which enables alpha-radiation-based cancer treatment for various types of solid tumors. Alpha DaRT delivers high-precision alpha radiation that is released when radioactive substances decay inside the tumor, according to the company. The short-range alpha particles ef...
Source: Mass Device - August 21, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Gynecological Oncology Regulatory/Compliance Alpha Tau Medical Source Type: news

A review of prevalent methods for automatic skin lesion diagnosis
(Bentham Science Publishers) The three prevalent skin cancers, according to the literature are melanoma, basal cell carcinoma and squamous cell carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 15, 2018 Category: International Medicine & Public Health Source Type: news

Second Primary Malignancy Risk Doubled After Head and Neck Cancer Second Primary Malignancy Risk Doubled After Head and Neck Cancer
The risk of second primary malignant neoplasm (SPMN) doubles after a first head and neck squamous cell carcinoma (HNSCC), especially when the site of the first cancer is not typically associated with malignancies due to human papillomavirus (HPV), according to a retrospective study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 27, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

HPV Vaccine Eliminates Advanced Skin Cancer in 97-Year-Old
TUESDAY, July 24, 2018 -- The 9-valent human papillomavirus (HPV) vaccine could be a therapeutic option for patients with cutaneous squamous cell carcinoma when surgical management is not an option, according to a case report published online July 3... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2018 Category: Pharmaceuticals Source Type: news

Pazopanib/Cetuximab Combo Promising in Recurrent, Metastatic Head and Neck Squamous Cell Carcinoma
A Washington University School of Medicine team ’s findings might inform future research into inhibitors of angiogenesis and PD-1 in head and neck cancer. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

HPV Shot Eliminates Advanced Skin Cancer in 97-Year-Old
FRIDAY, July 13, 2018 -- Two years ago, Ian McKenzie thought his mom's remaining days were dwindling. The 97-year-old woman had developed a severe case of what was thought to be an untreatable form of squamous cell carcinoma, the second leading form... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 13, 2018 Category: General Medicine Source Type: news

Living With Cancer: Understanding squamous cell carcinoma
Squamous cell carcinoma Squamous cell carcinoma is a common form of skin cancer that develops in the squamous cells that make up the middle and outer layer of your skin. Most often, the cause is prolonged exposure to ultraviolet (UV) radiation from sunlight, or from tanning beds or lamps. Avoiding UV light reduces your risk [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 6, 2018 Category: Databases & Libraries Source Type: news

Sylvester researcher uses HPV vaccine to treat patient with skin cancer
(University of Miami Miller School of Medicine) In 2017, a case report by Dr. Anna Nichols showed the HPV vaccine Gardasil reduced the number of new basal and squamous cell skin cancers in two patients. Tim Ioannides, M.D., a voluntary faculty member at UM, suggested using the vaccine as an off-label treatment by directly injecting it into the tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 3, 2018 Category: Cancer & Oncology Source Type: news

New diagnosis method could help spot head and neck cancers earlier
(IOP Publishing) Oral squamous cell carcinomas (OSCCs) are the most common head and neck cancers, but are often diagnosed late.Now, researchers in Germany have developed a new cell-based test that could help provide earlier and more reliable diagnosis of OSCCs.Writing in Convergent Science Physical Oncology, the researchers explain how they tested the mechanical properties of OSCC cells, and found they were 'softer' than benign cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 26, 2018 Category: Cancer & Oncology Source Type: news

Flight Attendants Have Higher Rates of Many Cancers, Study Says
Flight attendants are exposed to a number of known cancer-causing risks, but few studies have rigorously quantified that risk, and researchers say they are an understudied occupational group. The Harvard Flight Attendant Health Study (FAHS), begun in 2007, addresses some of the gaps in understanding health risks among flight attendants. In the latest report, published in the journal Environmental Health, researchers found that flight attendants had higher rates of many cancers, including breast cancer and melanoma, compared to the general population. The FAHS included more than 5,300 flight attendants who were recruited th...
Source: TIME: Health - June 26, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer healthytime Source Type: news

Peri-Implantitis and Squamous Cell Carcinoma
While Peri-implantitis has produced alot of research and is not an unusual occurrence, squamous cell carcinoma developing around dental implants is seldom described or reported.The postPeri-Implantitis and Squamous Cell Carcinoma appeared first onOsseoNews Dental Implants. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - June 14, 2018 Category: Dentistry Authors: osseonews Tags: Clinical Questions Research and News Source Type: news

Checkpoint inhibitor shrinks advanced squamous cell skin cancer
(University of Texas M. D. Anderson Cancer Center) Clinical trials show that an immune checkpoint inhibitor shrinks the tumors of nearly half of patients with an incurable, advanced form of a common skin cancer, an international team led by a researcher at The University of Texas MD Anderson Cancer Center reports in the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2018 Category: Cancer & Oncology Source Type: news

Merck's Keytruda extends lung cancer survival in two trials
CHICAGO (Reuters) - Merck& Co's immunotherapy Keytruda improved survival as a stand-alone treatment for newly-diagnosed lung cancer patients and with chemotherapy for hard-to-treat squamous cell lung cancer, new data released on Sunday showed, further cementing the company's lead in the most lucrative oncology market. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck's Keytruda shown to extend lung cancer survival in two trials
CHICAGO (Reuters) - New trial results show that Merck& Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard-to-treat squamous cell lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - June 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck's Keytruda boosts response in hard-to-treat lung cancer
(Reuters) - The combination of Merck& Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Spontaneous Regression of a Squamous Cell Lung Cancer Spontaneous Regression of a Squamous Cell Lung Cancer
What might be the mechanism behind the spontaneous regression of this patient's stage I squamous cell lung carcinoma?Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Should You Stop Wearing Sunscreen To Get More Vitamin D? Here ’s What a Doctor Says
Last year, a study published in The Journal of the American Osteopathic Association made headlines when it asserted that sunscreen use is partially to blame for widespread vitamin D deficiency worldwide. The research raised questions, given that consistently wearing sunscreen is one of the most common pieces of advice from physicians. Should the risk of vitamin D deficiency — which can lead to brittle bones and has been associated with insulin resistance, high blood pressure and decreased immune function, among other issues — overshadow years of that advice? Not according to Dr. Victoria Werth, a professor of d...
Source: TIME: Health - May 14, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime onetime public health Source Type: news

New biomarker identified for early diagnosis of lung cancer
(Elsevier) In a novel study in The American Journal of Pathology investigators found that CKAP4 levels were significantly higher in patients with lung cancer than in healthy individuals. They further determined that CKAP4 levels are already elevated in the blood of patients with stage I disease, making it a potential noninvasive diagnostic marker that could change current practices in the diagnosis and treatment of some types of lung cancer, including non-small-cell lung cancer and squamous cell carcinoma, and improve patient outcomes. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 8, 2018 Category: Biology Source Type: news

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, April 30, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologic... Biopharmaceuticals, Oncology, FDA Regeneron Pharmaceuticals, Sanofi, cemiplimab, squamous cell carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 30, 2018 Category: Pharmaceuticals Source Type: news

FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
PARIS and TARRYTOWN, N.Y., April 30, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 30, 2018 Category: Drugs & Pharmacology Source Type: news

Proactive Swallowing Rehab Program Helpful in Phalangeal CA
THURSDAY, April 26, 2018 -- A proactive speech and language pathology (SLP) program is beneficial for patients with head and neck squamous cell carcinoma (HNSCC), according to a study published online April 19 in JAMA Otolaryngology-Head& Neck... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2018 Category: Pharmaceuticals Source Type: news

A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment
The limited ability of cytotoxic T cells to infiltrate solid tumors hampers immune surveillance and the efficacy of immunotherapies in cancer. Adenosine accumulates in solid tumors and inhibits tumor-specific T cells. Adenosine inhibits T cell motility through the A2A receptor (A2AR) and suppression of KCa3.1 channels. We conducted three-dimensional chemotaxis experiments to elucidate the effect of adenosine on the migration of peripheral blood CD8+ T cells from head and neck squamous cell carcinoma (HNSCC) patients. The chemotaxis of HNSCC CD8+ T cells was reduced in the presence of adenosine, and the effect was greater o...
Source: Signal Transduction Knowledge Environment - April 24, 2018 Category: Science Authors: Chimote, A. A., Balajthy, A., Arnold, M. J., Newton, H. S., Hajdu, P., Qualtieri, J., Wise-Draper, T., Conforti, L. Tags: STKE Research Articles Source Type: news

Most Smokers With Head and Neck Cancer Have Tried to Quit
THURSDAY, April 19, 2018 -- Most active smokers with head and neck squamous cell carcinoma (HNSCC) have made one or more quit attempts, according to a study published online April 12 in JAMA Otolaryngology-Head& Neck Surgery. Samir S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 19, 2018 Category: Pharmaceuticals Source Type: news